Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › Connecticut
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa Connecticut keessatti
Qorannoo 4 Luukemiya Limfoositiikii Keessummaa f Connecticut keessatti hirmaatuu jiru.
Magaalota Connecticut keessatti
Takkalaa qorannoo (Ingiliffa)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Yale University Yale Cancer Center, New Haven
- Eastern Connecticut Hematology and Oncology, Norwich
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06943872A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Eastern CT Hematology & Oncology Associates ( Site 0033), Norwich
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06136559A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Yale Cancer Center, New Haven
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ado-2026 · NCT05131022A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Yale University School of Medicine /ID# 266224, New Haven
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Elb-2026 · NCT06428019Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.